Alto Neuroscience (ANRO) Projected to Post Earnings on Wednesday

Alto Neuroscience (NYSE:ANRO) is expected to announce its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect Alto Neuroscience to announce earnings of ($0.7345) per share for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 14, 2026 at 12:30 PM ET.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). On average, analysts expect Alto Neuroscience to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Alto Neuroscience Stock Up 4.3%

Shares of NYSE ANRO opened at $28.45 on Wednesday. The company has a debt-to-equity ratio of 0.07, a current ratio of 20.52 and a quick ratio of 20.52. The company has a 50-day moving average price of $24.38 and a 200-day moving average price of $22.09. The stock has a market capitalization of $998.31 million, a P/E ratio of -11.76 and a beta of 1.06. Alto Neuroscience has a 1 year low of $3.00 and a 1 year high of $28.85.

Wall Street Analysts Forecast Growth

ANRO has been the topic of several recent research reports. Robert W. Baird dropped their price target on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Monday, May 18th. Chardan Capital reissued a “buy” rating and issued a $30.00 price objective on shares of Alto Neuroscience in a research note on Wednesday, April 22nd. Wall Street Zen lowered Alto Neuroscience from a “sell” rating to a “strong sell” rating in a report on Saturday. Bank of America assumed coverage on Alto Neuroscience in a report on Tuesday, May 5th. They issued a “buy” rating and a $35.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Alto Neuroscience in a report on Wednesday, July 29th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $35.25.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ANRO. AQR Capital Management LLC bought a new position in shares of Alto Neuroscience during the 1st quarter worth $52,000. Invesco Ltd. bought a new stake in Alto Neuroscience in the 1st quarter valued at about $67,000. Bridgeway Capital Management LLC raised its stake in Alto Neuroscience by 85.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after acquiring an additional 25,000 shares during the period. Balyasny Asset Management L.P. purchased a new stake in Alto Neuroscience during the fourth quarter valued at about $198,000. Finally, OMERS ADMINISTRATION Corp bought a new position in Alto Neuroscience during the fourth quarter worth about $221,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.